These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 8579030)

  • 1. Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure.
    Krum H; Gu A; Wilshire-Clement M; Sackner-Bernstein J; Goldsmith R; Medina N; Yushak M; Miller M; Packer M
    Am Heart J; 1996 Feb; 131(2):337-41. PubMed ID: 8579030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure.
    Krum H; Sackner-Bernstein JD; Goldsmith RL; Kukin ML; Schwartz B; Penn J; Medina N; Yushak M; Horn E; Katz SD
    Circulation; 1995 Sep; 92(6):1499-506. PubMed ID: 7664433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study.
    Olsen SL; Gilbert EM; Renlund DG; Taylor DO; Yanowitz FD; Bristow MR
    J Am Coll Cardiol; 1995 May; 25(6):1225-31. PubMed ID: 7722114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.
    Circulation; 1995 Jul; 92(2):212-8. PubMed ID: 7600653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-blockade therapy in chronic heart failure: diastolic function and mitral regurgitation improvement by carvedilol.
    Capomolla S; Febo O; Gnemmi M; Riccardi G; Opasich C; Caporotondi A; Mortara A; Pinna GD; Cobelli F
    Am Heart J; 2000 Apr; 139(4):596-608. PubMed ID: 10740140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group.
    Cohn JN; Fowler MB; Bristow MR; Colucci WS; Gilbert EM; Kinhal V; Krueger SK; Lejemtel T; Narahara KA; Packer M; Young ST; Holcslaw TL; Lukas MA
    J Card Fail; 1997 Sep; 3(3):173-9. PubMed ID: 9330125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.
    Lancet; 1997 Feb; 349(9049):375-80. PubMed ID: 9033462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol.
    Metra M; Nodari S; D'Aloia A; Muneretto C; Robertson AD; Bristow MR; Dei Cas L
    J Am Coll Cardiol; 2002 Oct; 40(7):1248-58. PubMed ID: 12383572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy.
    Metra M; Nardi M; Giubbini R; Dei Cas L
    J Am Coll Cardiol; 1994 Dec; 24(7):1678-87. PubMed ID: 7963115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
    Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS
    J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulmonary function, cardiac function, and exercise capacity in a follow-up of patients with congestive heart failure treated with carvedilol.
    Guazzi M; Agostoni P; Matturri M; Pontone G; Guazzi MD
    Am Heart J; 1999 Sep; 138(3 Pt 1):460-7. PubMed ID: 10467196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
    Packer M; Bristow MR; Cohn JN; Colucci WS; Fowler MB; Gilbert EM; Shusterman NH
    N Engl J Med; 1996 May; 334(21):1349-55. PubMed ID: 8614419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonselective beta-adrenergic blocking agent, carvedilol, improves arterial baroflex gain and heart rate variability in patients with stable chronic heart failure.
    Mortara A; La Rovere MT; Pinna GD; Maestri R; Capomolla S; Cobelli F
    J Am Coll Cardiol; 2000 Nov; 36(5):1612-8. PubMed ID: 11079666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of carvedilol in congestive heart failure secondary to coronary artery disease.
    Das Gupta P; Broadhurst P; Raftery EB; Lahiri A
    Am J Cardiol; 1990 Nov; 66(15):1118-23. PubMed ID: 1977300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart.
    Gilbert EM; Abraham WT; Olsen S; Hattler B; White M; Mealy P; Larrabee P; Bristow MR
    Circulation; 1996 Dec; 94(11):2817-25. PubMed ID: 8941107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of carvedilol on systolic and diastolic left ventricular performance in idiopathic dilated cardiomyopathy or ischemic cardiomyopathy.
    Quaife RA; Gilbert EM; Christian PE; Datz FL; Mealey PC; Volkman K; Olsen SL; Bristow MR
    Am J Cardiol; 1996 Oct; 78(7):779-84. PubMed ID: 8857482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of nebivolol versus carvedilol on left ventricular function in patients with chronic heart failure and reduced left ventricular systolic function.
    Lombardo RM; Reina C; Abrignani MG; Rizzo PA; Braschi A; De Castro S
    Am J Cardiovasc Drugs; 2006; 6(4):259-63. PubMed ID: 16913827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of intravenous carvedilol, a new multiple action vasodilatory beta-blocker, in congestive heart failure.
    DasGupta P; Broadhurst P; Lahiri A
    J Cardiovasc Pharmacol; 1991; 18 Suppl 4():S12-6. PubMed ID: 1721973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of cold exposure on submaximal exercise performance and adrenergic activation in patients with congestive heart failure and the effects of beta-adrenergic blockade (carvedilol or metoprolol).
    Blanchet M; Ducharme A; Racine N; Rouleau JL; Tardif JC; Juneau M; Marquis J; Larivée L; Nigam A; Fortier A; White M
    Am J Cardiol; 2003 Sep; 92(5):548-53. PubMed ID: 12943875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial.
    Hori M; Sasayama S; Kitabatake A; Toyo-oka T; Handa S; Yokoyama M; Matsuzaki M; Takeshita A; Origasa H; Matsui K; Hosoda S;
    Am Heart J; 2004 Feb; 147(2):324-30. PubMed ID: 14760332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.